Top
Begin typing your search above and press return to search.

Phase II trial of Covaxin at GMCH

By Staff Reporter
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print

GUWAHATI, Aug 14 - Bharat Biotech and ICMR have picked Gauhati Medical College and Hospital (GMCH) as one of the testing centres for the Phase II trials of the indigenous COVID-19 vaccine Covaxin.

�Phase I trials of the vaccine has been successful. The second phase trial will start soon. I am happy that GMCH has been picked as one of the testing centres for the second phase trials,� Health Minister Himanta Biswa Sarma said, adding that paper works are on this regard.

According to the preliminary results of the Phase 1 trials, the COVID-19 vaccine is safe.

The Phase 1 trials are expected to be complete by end of August.

Phase II trials involve a larger pool of volunteers, split into focus groups of children, healthy adults and elderlies. Studies are done to study the safety, immuno-response, time taken to trigger a reaction and side-effects if any.

If the process continues smoothly, the vaccine should be available in the first half of 2021.

More in Entertainment
Next Story
Similar Posts
Phase II trial of Covaxin at GMCH

GUWAHATI, Aug 14 - Bharat Biotech and ICMR have picked Gauhati Medical College and Hospital (GMCH) as one of the testing centres for the Phase II trials of the indigenous COVID-19 vaccine Covaxin.

�Phase I trials of the vaccine has been successful. The second phase trial will start soon. I am happy that GMCH has been picked as one of the testing centres for the second phase trials,� Health Minister Himanta Biswa Sarma said, adding that paper works are on this regard.

According to the preliminary results of the Phase 1 trials, the COVID-19 vaccine is safe.

The Phase 1 trials are expected to be complete by end of August.

Phase II trials involve a larger pool of volunteers, split into focus groups of children, healthy adults and elderlies. Studies are done to study the safety, immuno-response, time taken to trigger a reaction and side-effects if any.

If the process continues smoothly, the vaccine should be available in the first half of 2021.

More in Entertainment
Similar Posts